Oxford Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Oxford Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-29,657	Closed	-$3.21M	–	1610
2019 Q4	$3.21M	Sell	29,657 -7,349	-20%	-$786K	0.09%	231
2019 Q3	$3.62M	Sell	37,006 -54,158	-59%	-$6.1M	0.09%	270
2019 Q2	$11.9M	Buy	+91,164	New	+$11.7M	0.26%	57
2019 Q1	–	Sell	-14,660	Closed	-$1.43M	–	2123
2018 Q4	$1.43M	Buy	+14,660	New	+$1.73M	0.04%	671
2018 Q3	–	Sell	-42,588	Closed	-$5.28M	–	2036
2018 Q2	$5.28M	Buy	42,588 +34,621	+435%	+$4.05M	0.1%	221
2018 Q1	$888K	Buy	+7,967	New	+$952K	0.02%	991
2017 Q4	–	Sell	-36,710	Closed	-$5.15M	–	1941
2017 Q3	$5.15M	Sell	36,710 -65,518	-64%	-$8.9M	0.1%	220
2017 Q2	$12.4M	Buy	+102,228	New	+$11.9M	0.25%	41
2015 Q1	–	Sell	-15,495	Closed	-$2.91M	–	783
2014 Q4	$2.91M	Buy	+15,495	New	+$2.87M	0.06%	297
2013 Q3	–	Sell	-8,772	Closed	-$809K	–	946
2013 Q2	$809K	Buy	+8,772	New	+$845K	0.02%	622

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Oxford Asset Management's ALXN Position: Q1 2020 in Review

Oxford Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 29,657 shares — an estimated $3.21M sold.

Oxford Asset Management first reported a position in ALXN in Q2 2013 and held it in 10 quarters. The position peaked at $12.4M in Q2 2017. 654 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

Oxford Asset Management reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 29,657 Alexion Pharmaceuticals shares in Q1 2020, an estimated $3.21M.
Oxford Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 10 quarters.
Oxford Asset Management's Alexion Pharmaceuticals position peaked at $12.4M in Q2 2017.
654 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.